Published on 19 Jul 2024 on Benzinga · via Yahoo Finance
Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage...
Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients
On Wednesday, ALX Oncology Holdings Inc. (NASDAQ:ALXO) released topline data from its Phase 2 ASPEN-06 clinical trial.
ASPEN-06 is evaluating evorpacept in combination with trastuzumab, Cyramza (ramucirumab), and paclitaxel (collectively, TRP) against TRP alone for HER2-positive gastric/GEJ cancer, where all patients had received an anti-HER2 agent in prior lines of therapy.